Selected News from Today's FirstWord

Merck & Co. to restructure R&D operations, cut jobs

Merck & Co. research chief Roger M. Perlmutter announced plans to cut jobs in the company's R&D operations as part of a strategic restructuring effort. "These changes are part of our existing strategy Full story

• Bristol-Myers Squibb, Simcere expand deal to include subcutaneous Orencia in China - (Ref. NJBIZ; FinanzNachrichten; Morningstar; Bristol-Myers Squibb)
• Elan puts itself up for sale - (Ref. FinanzNachrichten; Financial Times; Fidelity; The Kansas City Star; The Irish Times; Bloomberg; The Wall Street Journal; TheStreet; Shaw.ca; NASDAQ; Yahoo!Finance)
• Celgene reports positive Phase II data for apremilast in Behçet's disease - (Ref. Yahoo!Finance; MarketWatch; NASDAQ; FinanzNachrichten)
• Royalty Pharma says most Elan shareholders against Theravance, AOP Orphan deals - (Ref. PR Newswire; Bloomberg; Fidelity; FinanzNachrichten; NASDAQ)

Also in the News

• Products:
• bazedoxifene,
• codeine,
• dapagliflozin,
• Iluvien,
• insulin glargine,
• Kombiglyze,
• sitagliptin

• Companies:
• Astellas,
• Boehringer Ingelheim,
• IntelliCell BioSciences,
• Lineage Therapeutics,
• Novo Nordisk,
• Onconova Therapeutics,
• Teva

• Markets:
• Canada,
• EU,
• Italy,
• United States

Most Read Stories in the Past Week

• Novartis CEO discusses plans for Diovan patent expiration
• Pfizer records 5-percent rise in second-quarter profit
• Pfizer may introduce OTC version of Lipitor, sources say
• NICE provisionally rejects Novartis' oral MS drug Gilenya
• HHS drops case against Forest CEO